In summary, we expect ATIP1 could be a novel therapeutic target to prevent and treat metabolic disorders via innate immunity, with a reduction in macrophage infiltration and a change in the ratio of M1 to M2 macrophages in WAT. This evidence concerns the gene MTUS1 and metabolic disease.